Skip to main content
GH
NASDAQ Industrial Applications And Services

Guardant Health Reports Strong Q1 Results, Raises Full-Year Revenue Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$95.08
Mkt Cap
$12.102B
52W Low
$36.36
52W High
$120.74
52W Position info
161% above low
Off High info
21% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

GH has more than doubled off its 52-week low of $36.36.

Summary

Guardant Health announced robust first-quarter 2026 financial results, with revenue increasing 48% year-over-year, and significantly raised its full-year 2026 revenue guidance.


Key Events · Earnings and Guidance · GH

  • Strong Q1 2026 Revenue Growth

    Total revenue surged 48% year-over-year to $301.7 million, driven by strong performance in oncology and a more than 600% increase in screening revenue.

  • Raised Full-Year 2026 Revenue Guidance

    The company increased its 2026 revenue guidance to a range of $1.30 to $1.32 billion, representing 32% to 34% growth, up from the prior range of $1.25 to $1.28 billion.

  • Improved Non-GAAP Net Loss

    Non-GAAP net loss per share improved to $0.45 for Q1 2026, compared to $0.49 in the prior year period.

  • Operational Highlights

    The quarter included FDA approval for Guardant360® CDx as a companion diagnostic and new collaborations to expand access to its Shield screening tests.


Analysis · GH · Industrial Applications And Services

Guardant Health's robust first-quarter performance, marked by a 48% year-over-year revenue increase and significant growth in its screening segment, demonstrates strong operational momentum. The decision to materially raise full-year revenue guidance signals management's increased confidence in sustained growth and market adoption of its oncology and screening tests. This positive financial update, following recent FDA approval for Guardant360® CDx, reinforces the company's strong market position and execution.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GH was trading at $95.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $36.36 to $120.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GH - Latest Insights

GH
Nov 05, 2026, 5:13 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $130.02
Real-time Price: $137.49 info
Change: +$7.47 (+6%) info
Market Cap: $20.59B info
GH
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $159.34
Real-time Price: $137.49 info
Change: -$21.85 (-14%) info
Market Cap: $20.59B info
GH
Oct 08, 2026, 4:12 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $165.56
Real-time Price: $137.49 info
Change: -$28.07 (-17%) info
Market Cap: $20.59B info
GH
Sep 04, 2026, 3:44 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $156.46
Real-time Price: $137.49 info
Change: -$18.97 (-12%) info
Market Cap: $20.59B info
GH
Aug 24, 2026, 7:20 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $170.05
Real-time Price: $137.49 info
Change: -$32.56 (-19%) info
Market Cap: $20.59B info